Mallinckrodt plc (MNK): The stock had negative money flow to the tune of ($6.71 million) on Wednesday, which shows that the traders are selling the stock on the price strength. The inflow of money on upticks was $21.09 million, whereas, the outflow of money on downticks was $27.81 million and the ratio between the two was 0.76. The block trade had a negative net money flow of ($5.38 million). On the other hand, downticks amounted to $5.38 million of the traded value, which shows distribution in the stock by traders. Mallinckrodt plc (MNK) closed with marginal gains of 124 cents to end the day at $72.47, an increase of 1.74% over the previous days close. The stock recorded -5.03% for the week.
Mallinckrodt Public Limited Company has lost 2.19% in the last five trading days and dropped 2.33% in the last 4 weeks. Mallinckrodt Public Limited Company is up 20.98% in the last 3-month period. Year-to-Date the stock performance stands at -2.89%.
Mallinckrodt plc (MNK) : 11 brokerage houses believe that Mallinckrodt plc (MNK) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 12 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.04.
Mallinckrodt plc (NYSE:MNK): The stock opened at $70.74 and touched an intraday high of $72.9 on Wednesday. During the day, the stock corrected to an intraday low of $69.75, however, the bulls stepped in and pushed the price higher to close in the green at $72.47 with a gain of 1.74% for the day. The total traded volume for the day was 1,389,207. The stock had closed at $71.23 in the previous trading session.
Mallinckrodt public limited company (Mallinckrodt) is a global specialty pharmaceuticals company. The Company develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Companys Specialty Pharmaceuticals segment develops, manufactures and sells, through its Brands business, drugs, including EXALGO (hydromorphone HCl) Extended-Release Tablets and GABLOFEN. The Companys Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems (CMDS). The Company offers INOMAX Total Care (inhaled nitric oxide), a neonatal critical care product.